



SUMMARY OF CHANGES:

INSTRUMENT NOS. 77 to 84 of 2021

Statements of Principles Nos. 77 to 84 of 2021 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 25 June 2021. The day of commencement as specified in each of these Instruments is 26 July 2021.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from <http://www.legislation.gov.au>.

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar
Repatriation Medical Authority
GPO Box 1014
Brisbane Qld 4001

T +61 7 3815 9404
F +61 7 3815 9412
E info@rma.gov.au

7 July 2021

SUMMARY OF CHANGES

Instr. No.	Title	Date of Commencement	ICD-10-AM Code
REPEALS			
77 & 78/2021	familial adenomatous polyposis	26/07/2021	Nil
79 & 80/2021	solar keratosis	26/07/2021	L57.0
AMENDMENTS			
81 & 82/2021	hypopituitarism	26/07/2021	E23.0
83 & 84/2021	diabetes mellitus	26/07/2021	E10, E11, E12, E13 or E14

SUMMARY OF CHANGES

<p>77 & 78/2021</p>	<p>familial adenomatous polyposis</p>	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning <i>familial adenomatous polyposis</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p>For RH SoP (Instrument No. 77/2021)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and • revising the definition of 'relevant service' in Schedule 1 - Dictionary. <p>For BoP SoP (Instrument No. 78/2021)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and • revising the definition of 'relevant service' in Schedule 1 - Dictionary. <p>The determining of these Instruments finalises the investigation in relation to <i>familial adenomatous polyposis</i> as advertised in the Government Notices Gazette of 5 January 2021.</p>
<p>79 & 80/2021</p>	<p>solar keratosis</p>	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 23 April 2020 concerning <i>solar keratosis</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:</p> <p>For RH SoP (Instrument No. 79/2021)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the definition of 'solar keratosis' in subsection 7(2); • revising the reference to 'ICD-10-AM code' in subsection 7(4); • revising the factor in subsection 9(1) concerning having sunlight exposure to unprotected skin at the affected site, for clinical onset only, by the inclusion of a note; • new factor in subsection 9(2) concerning having sunburn as specified, for clinical onset only; • new factor in subsection 9(4) concerning having exposure of the affected region to welding light, while arc-welding metal without skin protection, for clinical onset only; • new factor in subsection 9(5) concerning undergoing organ or tissue transplantation, excluding corneal transplant, for clinical onset only; • revising the factor in subsection 9(6) concerning having PUVA therapy, for clinical onset only; • new factor in subsection 9(7) concerning taking hydroxyurea or voriconazole, for clinical onset only; • deleting the factor concerning being treated with an immunosuppressive drug, for clinical onset only, as this is now covered by the factor in subsection 9(5) concerning undergoing organ or tissue transplantation, excluding corneal transplant, for clinical onset only; • deleting the factor concerning having cutaneous contact of the affected site with bipyridyl compounds associated with paraquat manufacture, for clinical onset only; • new definitions of 'MRCA', 'organ or tissue transplantation', 'sunburn as specified' and 'VEA' in Schedule 1 - Dictionary; • revising the definition of 'relevant service' in Schedule 1 - Dictionary; and • deleting the definitions of 'an immunosuppressive drug' and 'paraquat'. <p>For BoP SoP (Instrument No. 80/2021)</p> <ul style="list-style-type: none"> • adopting the latest revised Instrument format, which commenced in 2015; • specifying a day of commencement for the Instrument in section 2; • revising the definition of 'solar keratosis' in subsection 7(2); • revising the reference to 'ICD-10-AM code' in subsection 7(4);

SUMMARY OF CHANGES

		<ul style="list-style-type: none"> • revising the factor in subsection 9(1) concerning having sunlight exposure to unprotected skin at the affected site, for clinical onset only, by the inclusion of a note; • new factor in subsection 9(2) concerning undergoing organ or tissue transplantation, excluding corneal transplant, for clinical onset only; • revising the factor in subsection 9(3) concerning having PUVA therapy, for clinical onset only; • deleting the factor concerning being treated with an immunosuppressive drug, as this is now covered by the factor in subsection 9(2) concerning undergoing organ or tissue transplantation, excluding corneal transplant, for clinical onset only; • new factor in subsection 9(4) concerning taking hydroxyurea or voriconazole, for clinical onset only; • new definitions of 'MRCA', 'organ or tissue transplantation' and 'VEA' in Schedule 1 - Dictionary; • revising the definition of 'relevant service' in Schedule 1 - Dictionary; and • deleting the definition of 'an immunosuppressive drug'. <p>On 19 March 2021, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instrument and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors from the reasonable hypothesis Statement of Principles relating to <i>having cutaneous contact of the affected site with bipyridyl compounds associated with paraquat manufacture, on more days than not for a cumulative period of at least five years, before the clinical onset of solar keratosis</i>. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instrument prior to its determination. No submissions were received for consideration by the Authority. No changes were made to the proposed Instrument following this consultation process.</p> <p>The determining of these Instruments finalises the investigation in relation to solar keratosis as advertised in the Government Notices Gazette of 23 April 2020.</p>
81 & 82/2021	hypopituitarism	<p>Amendment</p> <p>These instruments amend Statements of Principles Nos. 11 and 12 of 2019 concerning <i>hypopituitarism</i> by:</p> <p>For RH SoP (Instrument No. 11/2019)</p> <ul style="list-style-type: none"> • amending the definition of 'hypopituitarism' in subsection 7(2). <p>For BoP SoP (Instrument No. 12/2019)</p> <ul style="list-style-type: none"> • amending the definition of 'hypopituitarism' in subsection 7(2). <p>The determining of these Instruments finalises the investigation in relation to hypopituitarism as advertised in the Government Notices Gazette of 5 January 2021.</p>
83 & 84/2021	diabetes mellitus	<p>Amendment</p> <p>These instruments amend Statements of Principles Nos. 48 and 49 of 2020 concerning <i>diabetes mellitus</i> by:</p> <p>For RH SoP (Instrument No. 48/2020)</p> <ul style="list-style-type: none"> • replacing the existing factor in paragraph 9(6)(g) concerning 'taking an immune checkpoint inhibitor or an interferon', for clinical onset of type 1 diabetes mellitus; • revising the existing factor in paragraph 9(6)(h) concerning 'having infection with a Coxsackie B virus', for clinical onset of type 1 diabetes only; • inserting a new factor in subsection 9(13a) concerning 'taking an immune checkpoint inhibitor or an interferon', for clinical worsening; and • deleting the definition of 'having infection with a Coxsackie B virus' in Schedule 1 - Dictionary. <p>For BoP SoP (Instrument No. 49/2020)</p> <ul style="list-style-type: none"> • replacing the existing factor in paragraph 9(6)(e) concerning 'taking an immune checkpoint inhibitor or an interferon', for clinical onset of type 1 diabetes mellitus; and • inserting a new factor in subsection 9(13a) concerning 'taking an immune checkpoint inhibitor or an interferon', for clinical worsening. <p>The determining of these Instruments finalises the investigations in relation to diabetes mellitus as advertised in the Government Notices Gazette of 9 March 2021 and 6 April 2021.</p>